AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding AIM ImmunoTech Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 12 | 15 | +3 |
| Shares | 12.1K | 107.3K | +95.1K (+784.8%) |
| Value | $104.8K | $293.9K | +$189.0K (+180.3%) |
New holders (5)
Institutions that held AIM ImmunoTech Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 43,291 | $118.6K | 0.01% |
| Sabby Management, LLC | 28,855 | $79.1K | 0.41% |
| Vanguard Group Inc | 17,502 | $48.0K | 0.00% |
| Geode Capital Management, LLC | 16,186 | $44.3K | 0.00% |
| The PNC Financial Services Group, Inc. | 50 | $137 | 0.00% |
Sold out (2)
Institutions that held AIM ImmunoTech Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| CI Private Wealth, LLC | 10,001 | $86.5K |
| Danske Bank A/S | 3 | $26 |